Stratz, T. and Kees, Frieder and Mueller, W. (2003) Do cytochrome enzymes influence the therapeutic effect of tropisetron in fibromyalgia? DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 29 (2). pp. 91-94. ISSN 0378-6501
Full text not available from this repository.Abstract
It is well known that the 5-HT3 receptor tropisetron shows a bell-shaped dose-response curve in the treatment of pain associated with fibromyalgia. The best results are achieved with a daily oral dose of 5 mg for 10 days. Dosages of 10 and 15 mg per day have a much weaker effect. If tropisetron is administered by intravenous injection, a regimen of 5 mg per day over 5 days will suffice to reduce pain substantially. An open study of selected cases revealed that 2 mg of tropisetron daily for 5 days also yielded satisfactory pain reduction, whereas this was not observed in a placebo-controlled double-blind study. We therefore investigated which factors might be responsible for the different effects of the drug. Judging from the above-mentioned studies, the effect of a minimum dosage of tropisetron could be assumed to be partly attributable to the different half-life periods. This is supported by the markedly different rates of constipation, a characteristic side effect of the drug, reported by the two studies.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PARKINSONS-DISEASE; CYP2D6; |
| Subjects: | 600 Technology > 615 Pharmacy |
| Divisions: | Chemistry and Pharmacy > Institute of Pharmacy > Alumni or Retired Professors > Prof. Frieder Kees |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 22 Sep 2021 05:47 |
| Last Modified: | 22 Sep 2021 05:47 |
| URI: | https://pred.uni-regensburg.de/id/eprint/39438 |
Actions (login required)
 |
View Item |
